Breast Cancer - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 3149
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until March 3, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BA112F0CD07EN
Leaflet:

Download PDF Leaflet

Breast Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.

Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.

Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Breast Cancer Overview
Therapeutics Development
Breast Cancer - Therapeutics under Development by Companies
Breast Cancer - Therapeutics under Investigation by Universities/Institutes
Breast Cancer - Pipeline Products Glance
Breast Cancer - Products under Development by Companies
Breast Cancer - Products under Investigation by Universities/Institutes
Breast Cancer - Companies Involved in Therapeutics Development
Breast Cancer - Therapeutics Assessment
Drug Profiles
Breast Cancer - Dormant Projects 2934
Breast Cancer - Discontinued Products 3000
Breast Cancer - Product Development Milestones 3013
Appendix 3027

LIST OF TABLES

Number of Products under Development for Breast Cancer, H2 2016
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Development by Companies, H2 2016 (Contd..17)
Number of Products under Development by Companies, H2 2016 (Contd..18)
Number of Products under Development by Companies, H2 2016 (Contd..19)
Number of Products under Development by Companies, H2 2016 (Contd..20)
Number of Products under Development by Companies, H2 2016 (Contd..21)
Number of Products under Development by Companies, H2 2016 (Contd..22)
Number of Products under Development by Companies, H2 2016 (Contd..23)
Number of Products under Development by Companies, H2 2016 (Contd..24)
Number of Products under Development by Companies, H2 2016 (Contd..25)
Number of Products under Development by Companies, H2 2016 (Contd..26)
Number of Products under Development by Companies, H2 2016 (Contd..27)
Number of Products under Development by Companies, H2 2016 (Contd..28)
Number of Products under Development by Companies, H2 2016 (Contd..29)
Number of Products under Development by Companies, H2 2016 (Contd..30)
Number of Products under Development by Companies, H2 2016 (Contd..31)
Number of Products under Development by Companies, H2 2016 (Contd..32)
Number of Products under Development by Companies, H2 2016 (Contd..33)
Number of Products under Development by Companies, H2 2016 (Contd..34)
Number of Products under Development by Companies, H2 2016 (Contd..35)
Number of Products under Development by Companies, H2 2016 (Contd..36)
Number of Products under Development by Companies, H2 2016 (Contd..37)
Number of Products under Development by Companies, H2 2016 (Contd..38)
Number of Products under Development by Companies, H2 2016 (Contd..39)
Number of Products under Development by Companies, H2 2016 (Contd..40)
Number of Products under Development by Companies, H2 2016 (Contd..41)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Development by Companies, H2 2016 (Contd..29)
Products under Development by Companies, H2 2016 (Contd..30)
Products under Development by Companies, H2 2016 (Contd..31)
Products under Development by Companies, H2 2016 (Contd..32)
Products under Development by Companies, H2 2016 (Contd..33)
Products under Development by Companies, H2 2016 (Contd..34)
Products under Development by Companies, H2 2016 (Contd..35)
Products under Development by Companies, H2 2016 (Contd..36)
Products under Development by Companies, H2 2016 (Contd..37)
Products under Development by Companies, H2 2016 (Contd..38)
Products under Development by Companies, H2 2016 (Contd..39)
Products under Development by Companies, H2 2016 (Contd..40)
Products under Development by Companies, H2 2016 (Contd..41)
Products under Development by Companies, H2 2016 (Contd..42)
Products under Development by Companies, H2 2016 (Contd..43)
Products under Development by Companies, H2 2016 (Contd..44)
Products under Development by Companies, H2 2016 (Contd..45)
Products under Development by Companies, H2 2016 (Contd..46)
Products under Development by Companies, H2 2016 (Contd..47)
Products under Development by Companies, H2 2016 (Contd..48)
Products under Development by Companies, H2 2016 (Contd..49)
Products under Development by Companies, H2 2016 (Contd..50)
Products under Development by Companies, H2 2016 (Contd..51)
Products under Development by Companies, H2 2016 (Contd..52)
Products under Development by Companies, H2 2016 (Contd..53)
Products under Development by Companies, H2 2016 (Contd..54)
Products under Development by Companies, H2 2016 (Contd..55)
Products under Development by Companies, H2 2016 (Contd..56)
Products under Development by Companies, H2 2016 (Contd..57)
Products under Development by Companies, H2 2016 (Contd..58)
Products under Development by Companies, H2 2016 (Contd..59)
Products under Development by Companies, H2 2016 (Contd..60)
Products under Development by Companies, H2 2016 (Contd..61)
Products under Development by Companies, H2 2016 (Contd..62)
Products under Development by Companies, H2 2016 (Contd..63)
Products under Development by Companies, H2 2016 (Contd..64)
Products under Development by Companies, H2 2016 (Contd..65)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..10)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..11)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..13)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..14)
Breast Cancer - Pipeline by 3-D Matrix Ltd, H2 2016
Breast Cancer - Pipeline by 3-V Biosciences Inc, H2 2016
Breast Cancer - Pipeline by 3SBio Inc, H2 2016
Breast Cancer - Pipeline by 4SC AG, H2 2016
Breast Cancer - Pipeline by A&G Pharmaceutical Inc, H2 2016
Breast Cancer - Pipeline by AB Science SA, H2 2016
Breast Cancer - Pipeline by AbbVie Inc, H2 2016
Breast Cancer - Pipeline by AbGenomics International Inc, H2 2016
Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016
Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016
Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
Breast Cancer - Pipeline by Aduro BioTech Inc, H2 2016
Breast Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016
Breast Cancer - Pipeline by Advantagene Inc, H2 2016
Breast Cancer - Pipeline by Advaxis Inc, H2 2016
Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
Breast Cancer - Pipeline by Aegis Therapeutics LLC, H2 2016
Breast Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
Breast Cancer - Pipeline by Aerpio Therapeutics Inc, H2 2016
Breast Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016
Breast Cancer - Pipeline by Affichem SA, H2 2016
Breast Cancer - Pipeline by Agenus Inc, H2 2016
Breast Cancer - Pipeline by Agilvax Inc, H2 2016
Breast Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016
Breast Cancer - Pipeline by Alchemia Ltd, H2 2016
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016
Breast Cancer - Pipeline by Alissa Pharma, H2 2016
Breast Cancer - Pipeline by Almac Discovery Ltd, H2 2016
Breast Cancer - Pipeline by Alteogen Inc, H2 2016
Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016
Breast Cancer - Pipeline by Ambrx Inc, H2 2016
Breast Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
Breast Cancer - Pipeline by Amgen Inc, H2 2016
Breast Cancer - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
Breast Cancer - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016
Breast Cancer - Pipeline by Angion Biomedica Corp, H2 2016
Breast Cancer - Pipeline by ANP Technologies Inc, H2 2016
Breast Cancer - Pipeline by AntiCancer Inc, H2 2016
Breast Cancer - Pipeline by Antigen Express Inc, H2 2016
Breast Cancer - Pipeline by Antoxis Ltd, H2 2016
Breast Cancer - Pipeline by Aphios Corp, H2 2016
Breast Cancer - Pipeline by APIM Therapeutics AS, H2 2016
Breast Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
Breast Cancer - Pipeline by Aravive Biologics Inc, H2 2016
Breast Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
Breast Cancer - Pipeline by Armour Therapeutics Inc, H2 2016
Breast Cancer - Pipeline by Arno Therapeutics Inc, H2 2016
Breast Cancer - Pipeline by ArQule Inc, H2 2016
Breast Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
Breast Cancer - Pipeline by Arvinas Inc, H2 2016
Breast Cancer - Pipeline by Asana BioSciences LLC, H2 2016
Breast Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016
Breast Cancer - Pipeline by AskAt Inc, H2 2016
Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016
Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016 341

LIST OF FIGURES

Number of Products under Development for Breast Cancer, H2 2016
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Metastatic Breast Cancer - Pipeline Review, H2 2016 US$ 2,125.00 Dec, 2016 · 1096 pages

Ask Your Question

Breast Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: